

Global X China MedTech ETF (2841)

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X China MedTech ETF's (the "Fund's") objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index (the "Index").

The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.

The Fund may invest in small and/or mid-capitalisation companies. The stock of small-capitalisation and mid-capitalisation companies may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general.

The Fund's investments are concentrated in companies in the medical technology industry. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments and may be more susceptible to adverse economic, political, policy, liquidity, tax, legal or regulatory event affecting the relevant industry.

Many of the companies with a high business exposure to a medical technology theme have a relatively short operating history. Rapid changes could render obsolete the products and services offered by these companies and cause severe or complete declines in the prices of the securities of those companies. Additionally, companies with medical technology themes may face dramatic and often unpredictable changes in growth rates and competition for the services of qualified personnel. They may potentially subject to (i) substantial government intervention in the technology industry (including restrictions on investment in internet and technology companies), (ii) complex laws and regulations including privacy, data protection, content regulation, intellectual property, competition, protection of minors, consumer protection and taxation, (iii) heavy and significant capital investment on research and development, (iv) risks of medical failure (including injury or death of patients), negligence or product liability claims, recall or withdrawal of products. These risks may result in adverse impact of the operating results of the companies.

The Mainland China is an emerging market. The Fund invests in Mainland Chinese companies which may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risk, currency risks or control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility. Securities exchanges in the Mainland Chinese markets typically have the right to suspend or limit trading in any security traded on the relevant exchange. The government or the regulators may also implement policies that may affect the financial markets. All these may have a negative impact on the Fund.

Listed companies on the ChiNext market and/or STAR Board are subject to higher fluctuation on stock prices and liquidity risk, over-valuation risk, less stringent regulation risk, delisting risk and concentration risk.

The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Fund.

As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from redemption requests.

The trading price of the Shares on the Stock Exchange of Hong Kong is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund's Net Asset Value.

Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment. COM-2025.03.24-MKT-GXChinaETFsAtaGlance-V2

Permanent Innovator

<https://www.globalxetfs.com.hk/>



Global X China MedTech ETF (2841)



For Hong Kong
Investors Only

- Medtech sector recorded weak performance in 2024 dragged by multiple headwind including lingering anti-corruption impact and gradual implementation of VBP. Sector could see recovery in 2025 as supported by stimulus program and a lower base in 2024, and we already see sequentially improving tender statistics.
- MoF’s Buy China proposal should support accelerating import substitution, which bodes well for domestic leaders.
- Export value to overseas market recorded stable growth despite geopolitical risks. AI offers optionality for medtech companies to enhance products and solutions.

Key Information

| | |
|--|-------------------------------|
| Listing Date | 2023.08.03 |
| Ongoing Charges over a Year ¹ | 0.68% |
| Exchange | HKEX |
| Reference Index ² | Solactive China MedTech Index |


Source: Mirae Asset, February 2025. The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. As the Fund is newly set up, this figure is an estimate only and represents the sum of the estimated ongoing charges over a 12-month period, expressed as a percentage of the estimated average Net Asset Value of the Listed Class of Shares over the same period. It may be different upon actual operation of the Fund and may vary from year to year. As the Fund adopts a single management fee structure, the estimated ongoing charges of the Fund will be equal to the amount of the single management fee, which is capped at 0.68% of the average Net Asset Value of the Listed Class of Shares of the Fund. Any ongoing expenses exceeding 0.68% of the average Net Asset Value of the Listed Class of Shares of the Fund will be borne by the Manager and will not be charged to the Fund. For the avoidance of doubt, the single management fee does not include the fees relating to the FDIs, including swaps, entered into by the Fund. Please refer to the Product Key Facts and the Prospectus for further details. 2. The Underlying Index is a net total return, total market capitalisation weighted index. A net total return index seeks to replicate the overall return from holding a portfolio consisting of the Index constituents and in the calculation of the Index considers payments such as dividends after the deduction of any withholding tax or other amounts to which an investor holding the Index constituents would typically be exposed.

Top 10 Holdings

| Company Name | Weighting (%) |
|-----------------------|---------------|
| JD Health | 9.7 |
| Aier Eye Hospital | 9.0 |
| United Imaging | 8.8 |
| Mindray | 8.3 |
| Alibaba Health | 7.5 |
| IMEIK | 7.4 |
| Snibe | 5.1 |
| Jiangsu Yuyue Medical | 3.6 |
| APT Medical | 2.9 |
| Winning Health | 2.7 |


Source: Mirae Asset Global Investments, 28 February 2025

Category Breakdown




Source: Mirae Asset, March 2025

Medical Infrastructure – Stable Growth Driven by Government Supports




Source: NHS, JP Morgan, February 2025

Total Value of Medtech Tenders (by month) Recovered Sequentially




Source: UBS, February 2025

Overseas Market Presents Growth Potential Despite Geopolitical Risks




Source: UBS, February 2025

Market Share of Chinese Companies in Various Healthcare Categories (2024)




Source: Goldman Sachs, February 2025

Medical Equipment Sales Recovered As Bolstered by Policy Supports




Source: CITI, February 2025

Online Penetration in China Drug Market Continue to Increase



Source: UBS, 2024

China Medtech Leaders Have Substantial Growth Potential



Source: JP Morgan, January 2025

Fund Map

Global X ETFs Hong Kong



A lineup that spans emerging trends and disruptive tech, income, core and commodities ETFs. Or simply put, we strive to offer investors something beyond ordinary.

This document is intended for Hong Kong Investors only.
The following list consists of ETFs traded on the HKD counter (excluding USD and RMB counters). March 2025.

Investing in the Equity ETF(s) may expose to risks (if applicable) including general investment risk, equity market risk, sector/market concentration risk, active / passive investment management risk, tracking error risk, trading risk, risk in investing financial derivative instruments, securities lending risk, distributions paid out of capital or effectively out of capital risk.
Investing in the S&P Crude Oil Futures Enhanced ER ETF may expose to risks (if applicable) including passive investment risk, crude oil market risk, futures contracts risk, risk of material non-correlation with spot/current market price of the West Texas Intermediate crude oil risk, margin risk, trading risk, risk of investing in fixed income securities, tracking error risk, termination risk.
Investing in the USD Money Market Active ETF may expose to risks including general investment risk, active investment management risk, interest rate risk, risks associated with bank deposits, concentration risk, currency risk, trading risk, credit rating risk, downgrading risk, counterparty risk and distributions paid out of capital or effectively out of capital risk.
Investing in the Fixed Income Passive ETF(s) may expose to risks (if applicable) including general investment risk, passive investment management risk, interest rate risk, emerging markets risk, risks associated with PRC inter-bank bond market, Foreign Access Regime and Bond Connect, concentration risk, RMB/USD currency risk, securities lending risk, trading risk, credit rating risk, downgrading risk, counterparty risk, tracking error risk and distributions paid out of capital or effectively out of capital risk.
Investing in the Covered Call Active ETF may expose to risks (if applicable) including active investment management risk, futures contracts risk, margin requirement risk, failure of clearing house risk, concentration risk, securities lending transaction risks, currency risk, distributions paid out of capital or effectively out of capital risk, and trading risks.



THEMATIC GROWTH



INCOME

CHINA

DISRUPTIVE TECHNOLOGY

- 2845** Global X China Electric Vehicle and Battery ETF
- 3191** Global X China Semiconductor ETF
- 2826** Global X China Cloud Computing ETF
- 2807** Global X China Robotics and AI ETF

PEOPLE & DEMOGRAPHICS

- 2820** Global X China Biotech ETF
- 2841** Global X China MedTech ETF
- 2806** Global X China Consumer Brand ETF

PHYSICAL ENVIRONMENT

- 2809** Global X China Clean Energy ETF

MULTI-THEME

- 3050** Global X China Global Leaders ETF
- 2815** Global X China Little Giant ETF

GLOBAL

DISRUPTIVE TECHNOLOGY

- 3185** Global X FinTech ETF
- 3139** Global X Electric Vehicle and Battery Active ETF
- 3006** Global X AI & Innovative Technology Active ETF
- 3422** Global X Innovative Bluechip Top 10 ETF
- 3402** Global X G2 Tech ETF
- 3401** Global X AI Infrastructure ETF

ASIA

DISRUPTIVE TECHNOLOGY

- 3119** Global X Asia Semiconductor ETF

MULTI-THEME

- 3150** Global X Japan Global Leaders ETF
- 3184** Global X India Select Top 10 ETF
- 3158** Global X K-pop and Culture ETF
- 3084** Global X India Sector Leader Active ETF
- 3104** Global X Emerging Markets Asia Active ETF



COMMODITIES

COMMODITIES

- 3097** Global X S&P Crude Oil Futures Enhanced ER ETF



CORE

CORE

- 3040** Global X MSCI China ETF
- 2837** Global X Hang Seng TECH ETF
- 3029** Global X Hang Seng ESG ETF

DIVIDEND

- 3110** Global X Hang Seng High Dividend Yield ETF
- 3116** Global X Asia Pacific High Dividend Yield ETF
- 3419** Global X HSI Components Covered Call Active ETF
- 3416** Global X HSCEI Components Covered Call Active ETF
- 3417** Global X Hang Seng TECH Components Covered Call Active ETF

Dividend is not guaranteed and may be paid out of capital

FIXED INCOME

- 3059** Global X Bloomberg MSCI Asia Ex Japan Green Bond ETF
- 3041** Global X FTSE China Policy Bank Bond ETF
- 3137** Global X USD Money Market ETF
- 3075** Global X Asia USD Investment Grade Bond ETF
- 3450** Global X US Treasury 3-5 Year ETF
- 3440** Global X US Treasury 0-3 Month ETF

Disclaimer

This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service. The views and information discussed or referred in this document are Data as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the funds will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the funds and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment. Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (Hong Kong) Limited ("MAGIHK") are reliable, but we make no representation as to their accuracy or completeness. Reliance upon information in this material is at the sole discretion of the investor. Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGIHK as stipulated by local laws and regulations. This document is not directed to any person in any jurisdiction where availability of this document is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this document. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission or the applicable regulator in the jurisdiction and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGIHK. Copyright © 2025 Mirae Asset Global Investments. All rights reserved. COM-2025.03.11-MKT-fundmap-3417

Authors: HUANG Yimin and LIU Zijun (Licensed by the Securities and Futures Commission for Types 1 and 4 regulated activities under the Securities and Futures Ordinance). The authors and their associate(s) do not hold the securities/funds mentioned in the article.



EXPLORE
MORE